Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Cancer Immunol Res. 2016 Feb 10;4(4):323–336. doi: 10.1158/2326-6066.CIR-15-0168

Figure 5. F-IgG plus IL12 enhances monocyte effector functions in vitro but not in vivo.

Figure 5

(A) The lytic activity of freshly isolated normal monocytes stimulated with IL12 (10 ng/mL) in the presence of C-IgG or F-IgG coated KB tumor cells was determined in a standard 18 hour ADCC assay (combinatorial treatment was significantly higher than C-IgG or F-IgG at all E:T ratios with a P < 0.001). Normal monocytes were cultured with (B) plate-bound F‐IgG or (C) F-IgG coated FR+ KB tumor cells and culture supernatants were harvested after 48 hours then analyzed for TNFα and (D) IL12 by ELISA (* indicates P < 0.04). Results shown are representative of n ≥ 3 donors. (E) Mice depleted of monocytes/macrophages bearing subcutaneous L1210JF tumors were treated once every 4 days with murine C‐IgG (100 mg/kg) or F‐IgG (100 mg/kg) plus murine IL12 (2.5 ng).